American Vanguard (AVD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 3, 2026, with voting on director elections, auditor ratification, say-on-pay, and say-on-pay frequency proposals.
Seven directors are nominated, with board size reduced from nine to seven per new credit agreement requirements.
Deloitte & Touche LLP is recommended for reappointment as independent auditor for 2026.
Executive compensation is benchmarked against peers, with a pay-for-performance philosophy and significant alignment to company KPIs.
No related party transactions occurred in 2025.
Voting matters and shareholder proposals
Proposals include election of seven directors, auditor ratification, advisory vote on executive compensation, and advisory vote on frequency of say-on-pay.
Board recommends annual say-on-pay votes and approval of executive compensation.
No other business or shareholder proposals were submitted by the deadline.
Board of directors and corporate governance
Board size set at seven, with three directors not seeking reelection and one new independent nominee added per lender requirements.
Board committees include Audit, Compensation, Nominating & Corporate Governance, Finance, Risk, and a pro-tem Transaction Committee.
Five of seven director nominees are independent under NYSE standards.
Board met 15 times in 2025; all directors attended at least 75% of meetings.
Latest events from American Vanguard
- Gross margin and specialty growth offset global headwinds; 2026 guidance reaffirmed.AVD
Q2 2026 - Directors elected, auditor ratified, and ambitious growth targets set amid market headwinds.AVD
AGM 2026 - Q1 2026 sales up 7%, gross margin 31%, and adjusted EBITDA up 245% amid strong U.S. crop growth.AVD
Q1 2026 - 2025 margins and EBITDA held steady despite lower sales; 2026 targets growth and improved profitability.AVD
Q4 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 2024 - Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 2024 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 2024